Focus: Osteoporosis and Bone Repair
Previous clinical strategies focused on inhibiting fractures and slowing bone loss. Now molecular and cell biology research is paying dividends. A much deeper understanding of cell signaling has revealed that Bone Morphogenetic Proteins called BMP's are key messengers for the building process of bone. A comprehensive screening of agents to stimulate the correct BMP's has resulted in a therapeutic clinical solution for both the halting of bone deterioration in many elderly patients as well as the re-building of new bone for an enhanced quality of life.
Osteopenic Syndrome Bone Fractures In The Elderly Respond With Endogenous Anti-Catabolic Therapy
For an elderly patient, recovering from surgery or a fracture has been greatly assisted by the application of a non-androgenic steriodal agent such as Oxandrolone. Exogenous introductions of anabolic hormones are contra-indicated because of homeostatic dysregulation. Newer strategies rely on clinically efficacious stimulation of the patient's own glandular mechanisms for a more vigorous healing response in concert with homeostatic mechanisms.
Depression In Seniors Linked To Psychological Consequence Of Androgenetic Alopecia

The often significantly stressful impact of seeing one's former "crowing glory" become thin and deteriorate is one of the several stressors both elderly men and women cope with as they lose their former physical attributes through the aging process in conjunction with their associated self-concept. Typical resulting depression signs exhibited by the elderly include agitation, anxiety, extreme grief, insomnia and irritability. Treatment options that the physician can offer these patients are even more limited given the recently reported patient cases of trans-dermal systemic absorbtion of the hair growth agent minoxidil derived from the antihypertensive medication Loniten. Additionally, a published large scale study concluded that finasteride (Propecia) may accelerate certain aggressive forms of prostate cancer in some patients. Newer, less risky strategies have evolved that yield results from studies in follicular cell signalling and hair regrowth.
Prostate Cancer treatment is a rapidly evolving field. Chances are your urologist and oncologist are behind the times. Will they tell you that? Not very likely. It is up to the patient to be in charge of their own healthcare. It's an impossible position for a patient to be in, even if they are a doctor themselves. What is the answer? To hire a Medical Analyst who can navigate the waters and help the patient and their medical team chart the very best course of action. Contact us for more information.

Onychomycosis (nail fungus) And The Increased Risk For Infections Of Surrounding Tissues

Research on the nexus between diabetes, insulin levels and brittle bones emphasizes the danger for diabetics contracting mycotic bone infections. Diabetic patients suffer from poor circulation in the extremities combined with a lowered capacity to fight infection. This results in an alarming risk for onychomycosis or nail fungus. If not throughly treated, onychomycosis is not just a cosmetic embarrassment but instead can proliferate to skin and bone infections or even tissue death, resulting in inhibited mobility and complications ranging from patient depression to pain.

Significant research has been conducted to address the gap in patient care of dermatological fungus infections. Healthcare providers are faced with the difficult choice of either internal systemic medications or topical anti-mycotic agents. Different medical protocols have had their limitations. The internal medications have limited clinical effectiveness together with the challenges in patient compliance coupled with the significant risks of hepatic load, especially for patients disqualified as candidates because of pre-existing hepatic challenges. The topical agents also have only part of the equation addressed in that the infection is festering into the nail bed that is protected by the symptomatic nail itself. Few patients opt for podiatric removal of the nail, which would give the topical medicine a much better chance at achieving efficacy.
As common diseases in an aging population increase risk for onychomycosis, patient population statistics are expanding as infection rates grow.
Biomedical research in the area of fungal cell biology is moving in new and very interesting directions. Newer, more powerful and less toxic anti-mycotic agents are being tested in combination with transcutanious carrier technology that transports the medicine effectively to the nail bed where the infection can be more directly fought. This biomedical technology will help patients to avoid uncomfortable nail removal procedures and enable insurance to conserve valuable resources by heading off the spread of more serious sequential developments in vulnerable diabetic patients such as skin and bone infections.